Cancer

Tarlatamab, marketed under the brand name Imdelltra, is a novel bispecific T-cell engager (BiTE) antibody construct that has recently emerged as a promising treatment for extensive-stage small cell lung cancer (ES-SCLC). This article explores the mechanism of action, clinical trial results, and potential impact of Tarlatamab on cancer treatment. Mechanism of Action Tarlatamab is designed […]